A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors

Conclusions Although the progression free survival is similar to other VEGF inhibitors in NET, toxicity may preclude further investigation.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research